Overview

Topical SB-275833 Ointment, 1% For The Treatment Of Impetigo

Status:
Completed
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to determine if topical SB-275833 ointment, 1% is as safe and effective as topical sodium fusidate ointment, 2% for the treatment of impetigo in adults and children as young as 9 months of age.
Phase:
Phase 3
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Retapamulin